Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines

Anti-Cancer Drugs

Volumn 13, Issue 1, 2002, Pages 93-100

  Hoffmann, Thomas K ^a   Leenen, Katrin ^a   Hafner, Dieter ^a   Balz, Vera ^a   Gerharz, Claus D ^a   Grund, Adrian ^a   Balló, Hilmar ^a   Hauser, Ulrich ^a   Bier, Henning ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cisplatin; Head and neck cancer; Protein kinase C

Indexed keywords

CHELERYTHRINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SAFINGOL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ALKALOIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOPHENANTHRIDINES; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; PHENANTHRIDINES; PROTEIN KINASE C; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPHINGOSINE; TUMOR CELLS, CULTURED;

EID: 0036183807     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200201000-00011     Document Type: Article

References (48)

1. The role of protein kinase C in cell surface signal transduction and tumour promotion
2. Protein kinase C and lipid signaling for sustained cellular responses
3. Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C delta
4. Antagonistic effects of protein kinase C alpha and delta on both transformation and phospholipase D activity mediated by the epidermal growth factor receptor
5. Cross-talk between epidermal growth factor receptor and protein kinase C during calcium-induced differentiation of keratinocytes
6. Multisite phosphorylation of the epidermal growth factor receptor. Use of site-directed mutagenesis to examine the role of serine/threonine phosphorylation
7. Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation
8. Modulation of protein kinase C in antitumor treatment
9. Protein kinase C: A novel target for inhibiting gastric cancer cell invasion
10. Alterations in levels of different protein kinase C isotypes and their influence on behavior of squamous cell carcinoma of the oral cavity: Epsilon PKC, a novel prognostic factor for relapse and survival
11. Current trends in therapeutic research
12. Apoptosis and cancer chemotherapy
13. Epidermal growth factor receptor in head and neck squamous cell carcinomas
14. Antitumor activity of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma (HNSCC) lines
15. Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck
16. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
17. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
18. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum (II)
19. Cellular sensitization to cis-diamminedichloroplatinum (II) by novel analogues of the protein kinase C activator lyngbyatoxin A
20. Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum (II)
21. Comparison on protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells
22. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells
23. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C
24. Increased sensitivity to cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate
25. Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells
26. Establishment and characterization of cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79
27. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo
28. Chelerythrine is a potent and specific inhibitor of protein kinase C
29. Head and neck cancers
30. Establishment of carcinoma cell lines from the larynx and submandibular gland
31. Chemosensitivity of head and neck squamous carcinoma cell lines is not primarily correlated with glutathione level but is modified by glutathione depletion
32. Anti-(epidermal growth factor) receptor monodonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck
33. Mathematical analysis of concentration-response-relationships: A method for the evaluation of the ED50 and the number of receptor binding sites using a logit transformation
34. Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose response curves
35. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells
36. Rapid and long-term effects on protein kinase C on receptor tyrosinase phosphorylation and degradation
37. Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3′-kinase, and protein kinase C
38. Phorbol esters induce transient internalization without degradation of unoccupied epidermal growth factor receptors
39. Selective cleavage if the heregulin receptor erbb-4 by protein kinase C activation
40. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo
41. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C
42. Pharmacological inhibition of protein kinase C activity could induce apoptosis in gastric cancer cells by differential regulation of apoptosis-related genes
43. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells
44. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor Safingol alone and in combination with doxorubicin
45. Role of protein kinases in antitumor drug resistance
46. Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines
47. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha
48. Signaling and drug sensitivity